Prince Edward Island Becomes a National Leader in Providing Coverage for Dexcom G6 Continuous Glucose Monitoring System for Canadians With Diabetes
- With CGM now part of the Diabetes Canada Clinical Practice Guidelines, Dexcom CGM use is proven to improve glycemic control1,2 and can reduce the risk of costly long-term diabetes-related complications compared to fingerstick monitoring.3
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220601005584/en/
The Dexcom G6 CGM System is now covered by
“Today’s announcement is meaningful progress in achieving better access to real-time CGM technology for all Canadians living with diabetes. We thank the
The Dexcom G6 CGM System uses a small, wearable sensor and transmitter to continuously measure and send glucose levels wirelessly to a display device; and a compatible smart device* or receiver that displays real-time glucose data to users without the need for calibration† or scanning. The Dexcom G6 CGM System provides users with real-time alerts, including a predictive Urgent Low Soon alert, and can warn the user in advance of hypoglycemia — giving them time to take appropriate action before it occurs. With the use of the Dexcom Follow App‡, parents and caregivers can also access their loved one’s glucose levels remotely and be alerted if they are going out of their target glucose range. As part of the Diabetes Glucose Sensor Program, users will now be able to order and pick up their Dexcom CGM supplies through their local pharmacy.
In 2021, the Diabetes Canada Clinical Practice Guidelines review committee updated its recommendations for glucose monitoring, stating that real-time CGM (rtCGM), like the Dexcom G6, should be used by individuals with type 1 diabetes treated with basal-bolus insulin injections or an insulin pump in order to reduce A1C and increase time in range, reduce duration and incidence of hypoglycemia and, in adults, improve quality of life.4 The guidelines also state that adults living with type 2 diabetes using basal-bolus and not at target may use rtCGM to reduce A1C and duration of hypoglycemia.5
For more information about the coverage criteria for the Diabetes Glucose Sensor Program, please visit https://www.dexcom.com/en-CA/public-coverage#pei or this FAQ on
† If your glucose alerts and readings from the G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.
* For a list of compatible devices, please visit dexcom.com/compatibility
‡ Following requires the Dexcom Follow App and an Internet connection. Followers should always confirm readings on the Dexcom G6 App or Receiver before making diabetes treatment decisions.
1 Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: The DIAMOND randomized clinical trial. JAMA 2017;317(4):371-8.
2 Welsh JB, Gao P, Derdzinski M, et al. Accuracy, Utilization, and Effectiveness Comparisons of Different Continuous Glucose Monitoring Systems. Diabetes Technol Ther 2019;21(3):128-32.
3 Roze S, Isitt J,
4 Cheng AYY, Feig DS, Ho J, et al. Blood glucose monitoring in adults and children with diabetes: update 2021.
5 Cheng AYY, Feig DS, Ho J, et al. Blood glucose monitoring in adults and children with diabetes: update 2021.